Welcome to OCULAR Interface
Pioneering Ocular Diagnostics in London
Unveiling the Journey of Ocular Interface
At OCULAR Interface, we are dedicated to transforming the landscape of eye health through ground-breaking research and development. As a London-based R&D company, our focus lies in the development of advanced ocular biosensors designed to detect and monitor various eye diseases. Our mission is to provide early detection tools that revolutionize the way eye conditions are diagnosed, treated, and managed.
OCULAR Interface is a UK-based organization founded and led by Dr. Abhishek Mandal. We are a group of Vision Science experts and professional researchers whose primary goal is to disseminate knowledge regarding the limitless applications of AI in eye care. Through the platform of OCULAR Interface, we intend to keep you up-to-date about the groundbreaking research being carried out in the field of AI and Vision Sciences.
Many efforts have been done to interface the human eye with the machines in a seamless way and much progress has been made in this field. Innovations like eye tracking were present as early as the 1980s and now even more practical and advanced technologies are being integrated into this development. The introduction of smartphones and portable devices have rendered the use of this interface technology even more successful and tremendous data is collected each day which guarantees even further innovations in the future.
How Interfacing Is Achieved?
Interfacing with the eye gaze can be achieved in many ways (Santos, Santos, Jorge, & Abrantes, 2014). The earliest ways of interfacing included using physical implantation of electrodes surrounding the eye. The contraction of the muscles produces an electric current which is sensed by these electrodes and helps registers the eye movements. These signals can then be integrated with algorithms in the computer or machines to perform specific functions. In this way, the user achieves freedom from physical input and can control the interface with the mere blink of his eyes. This whole technique is called electrooculography (EOG) and forms the basis of modern day AI interfacing (Iáñez, Azorin, & Perez-Vidal, 2013).
The interfacing systems have now become largely independent of invasive approaches and use optical trackers instead. High-quality cameras are now able to detect intentional blinks and specific eye movements from the users. These actions are interpreted by means of algorithms and as a result, perform different actions. In a trial, people were able to navigate web pages and were able to emulate the functions of the keyboard and mouse just with the help of their vision. This interfacing holds great prospects for people who cannot speak or use their hands like in motor neuron disease, or paraplegia.
How Can The Data Help Improve AI?
As this technology becomes incorporated more and more into our daily lives, the data collected will be immense for the deep learning of new algorithms. The innovations are already making a large leap in eye care by early diagnosis of fatal diseases like age-related macular degeneration and diabetic retinopathy (Jacko et al., 2000). Eye-tracking and interfacing will help detect human behavior and can even be used to detect complex facial expressions and human emotions (Bozomitu, Păsărică, Tărniceriu, & Rotariu, 2019).
Apart from that, the AI algorithms can interpret the eye movements of psychiatric patients and help in their evaluation as well. AI has considerable success in detecting symptoms of anxiety in patients with attention deficit hyperactivity disorder (ADHD), autism, and bulimia nervosa.
On the retail side of things, big brands and stores are already using this technology to judge consumer behavior. They use similar methods of interfacing and try to see what the consumers are looking for when they are shopping for groceries.
Revolutionising Ocular Diagnostics with Cutting-Edge Biosensors
Our team of experienced researchers, engineers, and medical professionals is passionate about creating innovative solutions to enhance ocular diagnostics. Leveraging the power of emerging technologies, we are developing ocular biosensors that can accurately analyse and measure key biomarkers, pH levels, pressure, and other relevant factors within the eye.
These biosensors will play a pivotal role in the early detection and monitoring of a wide range of eye diseases, including glaucoma, age-related macular degeneration (AMD), diabetic retinopathy, cataracts, and various retinal disorders. By providing timely and accurate diagnostic information, our biosensors have the potential to improve patient outcomes and overall eye health.
Advancing Eye Health: Our Research and Development Phase
Currently, OCULAR Interface is in the research and development (R&D) phase. This critical stage allows us to explore and refine innovative technologies, conduct rigorous experiments, and gather comprehensive data to optimize the performance of our ocular biosensors.
Our team of experts collaborates closely with leading ophthalmologists, optometrists, and researchers to ensure that our biosensors meet the highest standards of accuracy, reliability, and safety. By adhering to strict scientific protocols and regulatory guidelines, we are dedicated to developing state-of-the-art ocular diagnostics solutions.
London: Our Home for Innovation
Located in the vibrant city of London, OCULAR Interface benefits from a thriving ecosystem of scientific research, technological innovation, and medical excellence. Being based in one of the world’s leading healthcare and research hubs allows us to collaborate with renowned institutions, access cutting-edge resources, and attract top talent in the field of ocular health.
Join Our Journey: Stay Informed and Connected
We invite you to join us on our journey to revolutionize ocular diagnostics and improve eye health outcomes. Stay informed about our progress, product releases, and other updates by visiting our official website. Be sure to subscribe to our newsletter to receive the latest news directly in your inbox.
Connect with us on social media to engage with our community, discover the latest advancements in ocular health, and participate in discussions surrounding the future of eye disease detection and treatment.
At OCULAR Interface, we are committed to advancing the frontiers of ocular health through our cutting-edge R&D efforts. Together, let us envision a world where early detection leads to better treatment and improved quality of life for individuals affected by eye diseases.
Applications Of AI In Vision Science
Besides human-computer interfacing, deep learning algorithms are now being deployed to diagnose gross changes in the structure and function of eye.
These include a plethora of ocular pathologies such as diabetic retinopathy and age-related macular degeneration (ARMD).
diabetic retinopathy
Age-related macular degeneration (ARMD)
With the help of efficient diagnostic AI tools, patients seldom need to travel long distances to visit their ophthalmologists.
Rather, AI software can scan the eye of a diabetic patient to accurately detect the degree of their retinopathy. It is noteworthy that the precision of AI in diagnosing ARMD-related changes can even be as high as 90%.
About Founder
Dr. Abhishek Mandal
Dr. Abhishek Mandal, the founder and lead researcher of OCULAR Interface, holds a Doctorate in Visual Neuroscience from Glasgow Caledonian University. Abhishek has obtained three post-graduate degrees in Vision Sciences, and is also the recipient of a Gold Medal in Vision Science studies. He is also the founder of Vision Science Academy (VSA), which is currently educating hundreds of vision science students throughout the globe.
